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Abstract
Background: Red blood cell (RBC) n-3 fatty acid status is related to various health outcomes. Accepted biological markers
for the fatty acid status determination are RBC phospholipids, phosphatidylcholine, and phosphatidyletholamine. The
analysis of these lipid fractions is demanding and time consuming and total phospholipid n-3 fatty acid levels might be
affected by changes of sphingomyelin contents in the RBC membrane during n-3 supplementation.
Aim:We developed a method for the specific analysis of RBC glycerophospholipids. The application of the new method in a
DHA supplementation trial and the comparison to established markers will determine the relevance of RBC GPL as a valid
fatty acid status marker in humans.
Methods: Methyl esters of glycerophospholipid fatty acids are selectively generated by a two step procedure involving
methanolic protein precipitation and base-catalysed methyl ester synthesis. RBC GPL solubilisation is facilitated by
ultrasound treatment. Fatty acid status in RBC glycerophospholipids and other established markers were evaluated in
thirteen subjects participating in a 30 days supplementation trial (510 mg DHA/d).
Outcome: The intra-assay CV for GPL fatty acids ranged from 1.0 to 10.5% and the inter-assay CV from 1.3 to 10.9%.
Docosahexaenoic acid supplementation significantly increased the docosahexaenoic acid contents in all analysed lipid
fractions. High correlations were observed for most of the mono- and polyunsaturated fatty acids, and for the omega-3
index (r = 0.924) between RBC phospholipids and glycerophospholipids. The analysis of RBC glycerophospholipid fatty acids
yields faster, easier and less costly results equivalent to the conventional analysis of RBC total phospholipids.
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Introduction
The supply of n-3 long chain polyunsaturated fatty acids (LC-
PUFA) is related to cardiovascular function, heart disease,
morbidity and mortality, and in the perinatal period to child
development [1,2]. Commonly used biological markers for the
dietary n-3 fatty acid intake are fatty acid composition of plasma or
serum phospholipids (PL), triacylglycerides (TAG), cholesterol esters
(CE), phosphatidylcholine (PC) and of red blood cell (RBC) PL, PC
and phosphatidylethanolamine (PE) [3,4]. The analysis of individual
lipid species requires lipid separation usually by thin layer
chromatography or solid phase extraction and the acid-catalysed
derivatisation of fatty acids. In recent years, novel methods were
developed avoiding these steps to reduce processing time and costs,
and to increase sample throughput [5]. The application of these
methods usually requires whole blood, plasma/serum, or RBC total
lipids for the evaluation of the fatty acid status. Good correlations
exist between fatty acid contents of these biological matrices and the
diet. This is similar to correlations found between dietary fat intake
and individual lipid classes [4].
Recently, our group developed a new, sensitive and robust
method for the selective determination of plasma glyceropho-
spholipids (GPL) fatty acids, which is independent of the
postprandial state of a subject [6]. The conventional lipid
extraction and separation has been replaced by the methanolic
precipitation of proteins with co-precipitation of TAG and CE. In
combination with a base catalysed synthesis of methyl esters at
room temperature, this ensures the specific transesterification of
GPL fatty acids [6]. In the past, it has been shown that extraction
procedures cannot easily be transferred from plasma to RBC [7].
Therefore, it is essential to test the applicability of the plasma GPL
method on RBC before its use in clinical studies.
The aim of the present study is to optimise and validate a new
method for the analysis of GPL in RBC membranes, which avoids
liquid-liquid extractions steps and chromatographic lipid class
isolation. The application of the new method in a DHA
supplementation trial and the comparison to established markers
such as RBC PL, PC and PE will determine the relevance of RBC
GPL as a valid fatty acid status marker in humans.
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Materials and Methods
Subjects
Thirteen healthy subjects (6 males, 7 females) from the Munich
area with an average age of 25.862.7 years (mean 6 SD) and a
BMI of 21.961.6 kg/m2 participated in an open-label, single-
group assignment supplementation study with DHA. Taking
supplements containing n-3 LC-PUFA or drugs interfering with
the lipid metabolism were exclusion criteria as well as fatty fish
consumption of more than once per week. The study was
registered at ClinicalTrials.gov (NC T01192269). The Ethical
Committee of the University of Munich Medical Center approved
the study (034-10) and participants signed informed consent forms
before they entered the study.
Study design and supplements
Participants were asked to take a 950 ml DHASCOH-S
microalgae oil capsule (Martek Biosciences, Columbia, MD)
during breakfast daily over a period of 30 days. The capsule
contained 520 mg DHA, but no other n-3 fatty acids. Participants
were asked to record the intake of the capsules including time and
date of consumption. Blood samples collected before and after the
intervention period were analysed. This study was part of a larger
project evaluating the DHA incorporation into plasma, RBC and
buccal cell GPL.
Sample preparation
After an overnight fasting period antecubital venous blood was
collected into 7.5 ml EDTA-containing monovettes (Sarstedt,
Nu¨mbrecht, Germany). Samples were directly placed on ice and
processed within 2 hours after collection. Plasma and RBC were
separated by centrifugation (10006g, 10 min, 4uC). RBC were
washed 3 times with saline solution (0.9% NaCl). For the
determination of PC and PE fatty acids aliquots of 500 ml RBC
were haemolysed with 250 ml distilled water and suspended in
8 ml isopropanol containing BHT (0.05%). For the analysis of PL
and GPL 100 ml aliquots of RBC were haemolysed with 100 ml
distilled water and suspended in 260 ml methanol containing BHT
(0.2%). All samples were stored at 280uC until analysis.
GPL fatty acid analysis
The method of Glaser et al. for the analysis of plasma GPL was
adapted for the determination of RBC GPL fatty acids [6,8].
Intra- and inter-assay analyses were performed to validate the
method before study commencement. In total 1.3 ml methanol
and 100 ml of internal standard solution (14.6 mg PC15:0 in
100 ml methanol; Sigma Aldrich, Taufkirchen, Germany) were
added to 200 ml haemolysed RBC. After continuous shaking on a
Vibrax shaker (IKA, Stauffen, Germany) at 1000 rpm for 5 min
samples were treated for 5 min in an ultrasound water bath
(40 kHz, 120 W). The RBC suspension was centrifuged at 30306g
for 10 min at 4uC to separate the methanolic supernatant from cell
fragments and precipitated proteins. After the transfer of the
supernatant into a 4 ml brown glass vial synthesis of fatty acid
methyl ester (FAME) was initiated by adding 50 ml sodium
methoxide solution (25 wt% in methanol; Sigma Aldrich). The
reaction was performed at room temperature and stopped after
4 min by adding 150 ml 3 M methanolic HCl (Sigma Aldrich).
FAME were extracted twice with 600 ml hexane and the extracts
were combined. Solvents were evaporated under a nitrogen flow
and FAME redissolved in 50 ml hexane containing BHT (0.2%).
Extracts were stored at 220uC until gas chromatographic (GC)
analysis.
Analysis of RBC PL fatty acids
1.8 ml chloroform, 540 ml methanol and 100 ml internal
standard solution (PC15:0 in methanol) were added to a thawed
RBC sample to obtain a chloroform-methanol ratio of 2:1 v/v for
lipid extraction [9]. A sodium chloride solution (2%) was added to
the solvent mixture to obtain phase separation after subsequent
centrifugation for 10 min at 30306g and 4uC. The organic phase
containing the lipids was dried under reduced pressure. The dried
extract was redissolved in 400 ml chloroform/methanol (1:1 v/v),
applied on a 20620 cm silica gel plate (Merck, Darmstadt,
Germany) and lipid classes were separated using heptane,
diisopropyl ether and acetic acid (60:40:3) as mobile phase [10].
Individual lipid bands were visualised with 2,7 di-chlor-fluorescein.
The PL band was scraped off and transferred into a brown glass
vial. FAME were synthesised in a closed vial with 3 N methanolic
HCl at 85uC for 45 minutes. Samples were neutralised with a
mixture of sodium carbonate, sodium hydrogen carbonate and
sodium sulphate (1:2:2, Merck, KGaA). FAME were extracted
twice with 1 ml hexane and redissolved in 50 ml hexane containing
BHT (0.2%). Samples were stored at 220uC until GC analysis.
Analysis of RBC PC and PE
The analysis of PC and PE in RBC membranes was performed
as previously described by Geppert et al. [11]. Briefly, after
extracting total lipids twice with 7 ml isopropanol/chloroform (3:2
v/v) and 3 ml chloroform, the solvents were evaporated under
reduced pressure. The separation of individual lipid fractions was
achieved by thin layer chromatography using chloroform/
methanol/ ammonia solution(25%)/distilled water (73:27:2,2:2,8
by vol) as mobile phase. Corresponding PC and PE bands were
scraped of the plate and transferred into 4 ml brown glass vials.
FAME for GC analysis were obtained as describe above.
Gas chromatography
FAME were quantified by GC with flame ionisation detection
(Agilent 5890 series II, Waldbronn, Germany). The applied
settings have previously been published by Glaser et al [6]. Peak
integration was performed with EZChrom Elite (Version 3.1.7,
Agilent).
Statistical analysis
Relative fatty acid contents (% wt/wt) were calculated based on
20 cis-fatty acids and presented as mean and standard deviation.
Precision analyses were performed by analyzing 8 aliquots of one
RBC sample at the same day (intra-assay) or 26 aliquots over a
period of 2 months (inter-assay) and calculated as coefficient of
variation (CV). Intra-laboratory method performance were tested
by comparing intra-assays (n = 8) of different staff members.
Statistics for evaluating the effect of storage was performed with
ANOVA repeated measures. The effect of DHA supplementation
on fatty acid contents of different lipid fractions was assessed using
paired t-tests. Relative DHA changes from baseline between PC,
PE, GPL and PL were assessed with one-way ANOVA and
Bonferroni post-hoc test. Correlations between fatty acid contents
of different RBC compartments were evaluated according to
Pearson. P-values ,0.05 were considered to be statistically
significant. All statistical analyses were computed using IBM SPSS
Statistics for Windows, Version 19.0.0.1.
Results
Table 1 shows the intra- and inter-assay data of RBC samples
donated by different volunteers. The CV of the intra-assay
evaluation (n= 8) ranged from 1.0 to 10.5% for all fatty acids and
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was ,5% in most fatty acids. The inter-assay reproducibility
(n = 26) was comparable to that of the intra-assay for all fatty acids
(CV 1.3–10.9%), which contributed more than 0.5% to total fatty
acids. Moreover, the inter-observer variability was tested by three
different laboratory members, which achieved constantly a CV
,10% for the 20 analysed RBC GPL fatty acids.
The extraction efficiency for of GPL was tested by applying 4
different extraction procedures (Figure 1). In total 16 aliquots
(464) of an RBC sample were tested. Continuous shaking of RBC
dissolved in methanol for 5 min yielded in 1856120 mg total GPL
fatty acids per 100 ml RBC, which was similar to prolonged
shaking for 10 min (241663 mg) or additional ultrasound
treatment for another 5 min (301646 mg). Adding methanol to
RBC without shaking caused clotting of RBC and lower recovery
(37624 mg). Partial clotting was also observed after shaking the
samples for 5 or 10 min, but not when samples were treated with
ultrasound. The fatty acid pattern of the 16 RBC aliquots did not
differ to any appreciable extent (data not shown).
Contamination of the GPL containing supernatant with TAG
and CE fatty acids was evaluated by separating lipid fractions in the
methanolic supernatant via thin layer chromatography prior to the
base-catalysed transesterification. Based on GPL total fatty acids the
contamination originating from TAG fatty acids was 0.9% and
from CE 0.4%. Only palmitic-, stearic-, oleic-, and linoleic acids
derived from TAG or CE were detected.
Changes in fatty acid compositions caused by long-term storage
are shown in Table 2. Washed RBC were kept in methanol
containing BHT (0.2%) for 8 months at280uC. Differences in fatty
acid compositions were calculated based on changes relative to
baseline and expressed in percent. Significant differences were
found for some fatty acids, but values determined without storage
were less than 10%, except for C17:0 (+29.5%), C18:3n-6 (+32.0%)
and C22:4n-6 (+15.8%). The contribution of the first two fatty acids
to total fatty acids was less than 0.5%. Palmitic acid was not affected
under these storage conditions, whereas stearic acid decreased
slightly (22.8%). Fatty acids with a high potential for oxidative
damage, such as n-3 and n-6 PUFA were affected differently.
During storage the DHA percentage changed by 6.3%, (p= 0.061),
whereas arachidonic acid (ARA) contents increased by 3.7%
(p= 0.160), but differences were not statistically significant.
Table 3 shows the fatty acid composition of individual PL
classes and total PL before and after the supplementation period.
The micro algae oil supplementation increased DHA contents
relative to baseline in PC by 92.3%652.1, which was higher then
in PE (33.2%616.0), GPL (27.4%616.5) and PL (13.3%616.0)
(ANOVA; P,0.001). ARA levels decreased during the supple-
mentation period, which was significant in PL (29.5%) and GPL
(23.9%), but not in PE (20.6%) or PC (26.9%). Similar results
were shown for n-3 and n-6 docosapentaenoic acid (DPA). EPA
was not affected by the supplementation, although by trend a
slight increase could be observed in all fractions. At the beginning
of the study contents of stearic acid in PC (10.7%61.1) and PE
(8.4%61.1) were lower then in GPL (17.3%60.5) or PL
(18.5%60.7), whereas oleic acid was more abundant in PC
(17.2%61.1) and PE (17.3%60.9) then in GPL (14.6%60.8) or
PL (13.3%60.8). All other GPL and PL fatty acid contents ranged
between the levels of the respective fatty acids of PE and PC. The
DHA supplementation had no effect on these observations.
Relationships of individual fatty acids between GPL and PC, PE
or PL before and after the supplementation period are shown in
Table 4. In general, SFA did not correlate between the different
lipid fractions. At the beginning of the study high correlations were
found for DHA between GPL/PE (r= 0.818) and GPL/PL
(r= 0.940), and a good correlation between GPL/PC (r= 0.555).
Similar correlations were shown for other n-3 and n-6 fatty acids,
such as EPA, n-6 DPA and di-homo-c-linolenic acid. GPL ARA
contents were only correlated with PC ARA levels (r = 0.625), but
not with ARA contents of the other fractions. The supplementation
of micro algae oil influenced the correlations of individual fatty
acids. The correlation of DHA between GPL/PE (r= 0.725) and
GPL/PL (r = 0.729) was lower than at the beginning of the study.
No correlations were found for DHA between GPL and PC. ARA,
which did not correlate between GPL and PE showed a significant
r-value of 0.657 after supplementation. The changes were most
significant between GPL and PL as for most of the n-3 and n-6 fatty
acid no longer correlations were found, except for DHA (r= 0.729),
a-linolenic acid (r = 0.853) and di-homo-c-linolenic acid (r = 0.874).
Omega-3-indices based on GPL and PL were calculated from
data determined at study start (Figure 2). The sum of EPA and
DHA percentages was highly correlated between both lipid
fractions (r = 0.924; P,0.001). At the end of the study a
correlation of r = 0.780 (P=0.002) was found.
Discussion
This study shows that the analysis of RBC GPL is well suited for
a fatty acid status determination in human. The base-catalyzed
Table 1. Intra- and inter-assay reproducibility of the GPL fatty
acid analysis.
Intra-assay (n =8) Inter-assay (n=26)
Mean SD CV [%] Mean SD CV [%]
Saturated Fatty Acids
C14:0 0.35 0.01 3.7 0.32 0.04 12.6
C16:0 22.99 1.01 4.4 23.31 0.80 3.4
C17:0 0.34 0.02 4.6 0.32 0.04 11.3
C18:0 18.34 0.27 1.5 17.92 0.40 2.3
Monounsaturated Fatty Acids
C16:1n-7 0.29 0.02 7.6 0.35 0.03 8.6
C18:1n-7 1.45 0.03 2.0 1.42 0.15 10.9
C18:1n-9 14.07 0.22 1.5 13.38 0.22 1.6
C20:1n-9 0.29 0.00 3.3 0.27 0.01 4.9
n-9 Polyunsaturated Fatty Acids
C20:3n-9 0.11 0.00 4.2 0.11 0.01 9.5
n-6 Polyunsaturated Fatty Acids
C18:2n-6 11.84 0.50 4.3 12.34 0.16 1.3
C18:3n-6 0.06 0.00 3.7 0.08 0.01 10.1
C20:2n-6 0.22 0.01 6.4 0.25 0.01 5.3
C20:3n-6 2.37 0.02 1.0 2.21 0.04 1.7
C20:4n-6 15.39 0.84 5.5 15.57 0.55 3.5
C22:4n-6 2.37 0.25 10.5 3.20 0.20 6.3
C22:5n-6 0.67 0.02 3.0 0.64 0.03 5.0
n-3 Polyunsaturated Fatty Acids
C18:3n-3 0.15 0.01 4.6 0.10 0.01 8.7
C20:5n-3 0.75 0.04 5.5 0.69 0.05 6.6
C22:5n-3 2.35 0.22 9.3 2.31 0.14 6.2
C22:6n-3 5.68 0.17 2.9 5.16 0.26 5.0
Mean and SD are expressed as %wt/wt.
doi:10.1371/journal.pone.0033874.t001
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Figure 1. Recovery of total RBC fatty acids using different extraction procedures (P,0.05).
doi:10.1371/journal.pone.0033874.g001
Table 2. Changes in fatty acids (%wt/wt) during storage of RBC samples (n = 13) in methanol over a period of 8 months at 280uC.
Analysis without storage Analysis after 8 months storage Difference*
Mean SD Mean SD [%] P
C14:0 0.28 0.07 0.29 0.08 4.09 ,0.001
C16:0 22.62 1.21 22.81 1.00 0.85 n.s.
C17:0 0.33 0.04 0.42 0.08 29.50 ,0.001
C18:0 17.75 0.55 17.26 0.58 22.75 ,0.001
C16:1n-7 0.35 0.13 0.37 0.14 6.90 n.s.
C18:1n-7 1.35 0.11 1.39 0.12 3.32 n.s.
C18:1n-9 15.04 0.89 14.73 0.74 22.03 0.040
C20:1n-9 0.31 0.07 0.29 0.04 27.59 n.s.
C20:3n-9 0.11 0.03 0.10 0.02 23.45 n.s.
C18:2n-6 11.79 1.29 11.57 1.10 21.90 n.s.
C18:3n-6 0.06 0.03 0.07 0.03 31.97 0.014
C20:2n-6 0.28 0.04 0.26 0.03 26.41 n.s.
C20:3n-6 1.91 0.43 1.82 0.39 24.42 n.s.
C20:4n-6 16.04 1.24 16.63 0.86 3.69 n.s.
C22:4n-6 2.76 0.44 3.19 0.52 15.79 0.004
C22:5n-6 0.78 0.15 0.70 0.15 29.74 0.048
C18:3n-3 0.14 0.03 0.14 0.03 21.15 n.s.
C20:5n-3 0.58 0.21 0.60 0.20 3.10 n.s.
C22:5n-3 2.04 0.31 2.22 0.35 8.44 n.s.
C22:6n-3 5.61 1.16 5.26 0.93 26.30 n.s.
*Differences in fatty acid contents caused through sample storage were related to fatty acid contents of samples without storage. Mean and SD are expressed as %wt/
wt. n.s.: not significant.
doi:10.1371/journal.pone.0033874.t002
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transesterification of RBC GPL fatty acids presented here has been
applied for the analysis of plasma and cheek cell GPL before
[6,8,12]. A good precision and robustness, a high sample
throughput and a low-sample volume distinguish this method
from fatty acid analyses using chromatographic separation of lipid
fractions [13]. RBC GPL fatty acids before and after DHA
supplementation were very similar to the fatty acid composition of
total RBC PL analysed by the much more cumbersome
conventional methodology.
A major challenge was clotting of RBC in methanol, which
affected the total GPL fatty acid recovery. Extending the shaking
time of RBC in methanol to 10 min had little effect on clot
formation, but variations between measurements decreased
compared to shorter shaking periods of 5 min. The application
of ultrasound (indirect application in a water bath) after shaking
resulted in a fine grained RBC suspension. The ultrasound
treatment increased the recovery rate of the total fatty acid
concentration and further decreased the variation of results
between measurements. However, the PC standard did not
compensate for the differences in extraction efficacy. We assume
that the inclusion of PL into clots causes the loss of PL and not the
partitioning of PL between solid and liquid phase during
extraction, in line with the observation that fatty acid compositions
were not affected. The ultrasound treatment is an integral part of
the procedure to optimise recovery. Ultrasound treatment of
5 min seems to be sufficient to totally disperse the RBC clots in
methanol.
For the analysis of GPL fatty acids in plasma an intra-assay CV
of ,3.7% and inter-assay CV of ,10.7% was achieved for all
studied fatty acids [6]. The precision of the fatty acid analysis in
cheek cells was comparable, with CV ranging from 0.7% to 14.1%
[12]. The precision data determined in this study for RBC were
similar. This shows that the two step procedure, methanolic
protein precipitation and base catalysed transesterification, is
reliable for the GPL fatty acid determination in plasma, RBC, and
cheek cells.
Storage of RBC samples over a longer period may be necessary
in trials with large subject numbers [14]. Fatty acids of RBC
samples are stable at temperatures below 250uC with or without
free radical scavenging or iron binding agents [15]. Treating the
washed RBC samples prior to freezing seems unnecessary, but
when adding BHT a solvent is required as this antioxidant is
insoluble in water. When our samples were stored in methanol
containing BHT (0.05 mg/ml of RBC) for 8 months at 280uC,
Table 3. Effects of DHA supplementation on fatty acid composition (%wt/wt) of individual RBC PL fractions.
PC PE GPL PL
study start study end study start study end study start study end study start study end
mean SD mean SD
%
diff mean SD mean SD
%
diff mean SD mean SD
%
diff mean SD mean SD
%
diff
C16:0 36.2 1.3 36.0 1.4 20.5 17.7 1.9 17.3 1.5 22.6 22.4 1.1 22.8 0.8* 1.9 25.6 1.1 27.6 1.5* 8.0
C18:0 10.6 1.1 10.4 1.1 21.6 8.4 1.1 8.1 0.5 23.6 17.3 0.5 16.8 0.6** 23.0 18.5 0.7 19.1 1.4 4.7
C16:
1n-7
0.6 0.2 0.6 0.2 15.6 0.3 0.1 0.2 0.1 26.7 0.4 0.1 0.4 0.1 25.7 0.3 0.1 0.4 0.1 46.4
C18:
1n-7
2.0 0.1 2.1 0.1 1.0 1.4 0.3 1.3 0.1 29.0 1.4 0.1 1.3 0.1* 25.3 1.2 0.2 1.1 0.1 23.9
C18:
1n-9
17.2 1.1 17.0 1.1 21.4 17.3 0.9 17.0 1.2 28.8 14.6 0.8 14.5 0.7 20.7 13.3 0.8 13.1 0.7* 21.7
C20:
3n-9
0.1 0.0 0.1 0.0 23.3 0.1 0.0 0.1 0.0 8.6 0.1 0.0 0.1 0.0 25.8 0.1 0.0 0.1 0.0 31.1
C18:
2n-6
19.5 1.6 19.7 1.6 1.2 5.6 0.9 5.4 0.9 24.0 11.6 1.2 11.3 1.0 22.1 10.2 1.0 9.9 0.8 22.1
C18:
3n-6
0.1 0.0 0.1 0.0 26.4 0.1 0.0 0.1 0.0 0.4 0.1 0.0 0.1 0.0 25.0 0.1 0.0 0.1 0.0 20.5
C20:
3n-6
2.1 0.6 2.1 0.5 22.9 1.3 0.3 1.2 0.2 23.4 1.9 0.4 1.7 0.4*** 27.7 1.6 0.5 1.4 0.4*** 214.6
C20:
4n-6
6.8 1.0 6.4 0.9 25.8 25.4 1.9 25.5 1.4 20.6 16.8 0.9 16.1 0.7* 23.9 16.3 1.1 14.7 0.9*** 29.5
C22:
4n-6
0.4 0.1 0.3 0.0 26.9 8.2 1.1 7.8 1.0* 26.0 3.1 0.6 3.2 0.5 2.2 3.7 0.4 3.1 0.4*** 216.2
C22:
5n-6
0.2 0.1 0.1 0.0 23.0 1.0 0.2 0.9 0.2** 213.3 0.7 0.2 0.7 0.1*** 211.0 0.6 0.2 0.4 0.2*** 236.7
C18:
3n-3
0.2 0.1 0.2 0.1 19.3 0.1 0.0 0.1 0.0 15.1 0.1 0.0 0.1 0.0 2.0 0.1 0.0 0.1 0.0 29.7
C20:
5n-3
0.5 0.4 0.5 0.1 27.5 1.0 0.3 1.0 0.3 4.3 0.6 0.3 0.6 0.1 9.3 0.6 0.2 0.6 0.2 9.5
C22:
5n-3
0.5 0.1 0.4 0.1* 212.5 4.5 0.6 4.2 0.6*** 27.9 2.3 0.4 2.1 0.3 24.4 2.3 0.3 1.9 0.4** 217.4
C22:
6n-3
1.4 0.2 2.6 0.5*** 92.3 6.2 0.9 8.3 0.9*** 33.2 4.6 0.8 5.8 0.6*** 27.3 4.3 0.8 4.9 0.9** 13.3
Differences between study start and end were based on baseline values. Paired t-test: *p,0.05, **p,0.01, *p,0.001.
doi:10.1371/journal.pone.0033874.t003
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most of the fatty acid proportions did not change to an appreciable
extent from pre-storage values. This is comparable with other
published RBC conservation methods, which stored samples for
12 months or longer [14,15,16,17]. However, a non significant
trend towards a selective degradation of DHA was observed, and
losses might become significant after 12 months of storage.
Increasing the BHT concentration in the sample [15] or excluding
the hemolysis of RBC with distilled water prior to freeze storage
[14,17] might improve the DHA stability, but this needs to be
determined for GPL bound DHA.
The supplementation of micro algae oil, rich in DHA,
significantly increased the DHA contents of PC and PE in the
study subjects. The relative increase in PC was higher then in PE,
which has also been described by other authors [11,18,19]. The
non-uniform distribution of PC and PE in the RBC membrane
and the different mechanisms for the fatty acid exchange of PC
and PE with plasma may explain these observations.
SM in the RBC membrane behave differently during n-3
intervention and may affect the n-3 fatty acid status determination,
as PC and PE proportions decrease and the SM proportion
increases slightly with n-3 LC-PUFA supplementation [20]. This
might be explained by the fact that the RBC membrane
homeostasis is not only maintained by the exchange of other
highly unsaturated fatty acids with DHA, i.e. ARA, but also by an
increase of SM, which counteracts effects of high n-3 levels in PC
or PE on membrane fluidity [21]. Our findings of increased SFA
Table 4. Correlations between RBC GPL fatty acids and other RBC PL fractions before and after n-3 supplementation.
Correlation of individual GPL fatty acids before study:
PC PE PL
R P R P R P
C16:0 0.525 n.s. 0.081 n.s. 0.343 n.s.
C18:0 0.529 n.s. 0.291 n.s. 0.162 n.s.
C16:1n-7 0.801 0.001 0.893 ,0.001 0.874 ,0.001
C18:1n-7 0.509 n.s. 0.725 0.005 0.409 n.s.
C18:1n-9 0.919 ,0.001 0.441 n.s. 0.898 ,0.001
C20:3n-9 0.352 n.s. 0.142 n.s. 0.743 0.006
C18:2n-6 0.797 0.001 0.446 n.s. 0.970 ,0.001
C18:3n-6 0.436 n.s. 0.104 n.s. 0.427 n.s.
C20:3n-6 0.766 0.002 0.905 ,0.001 0.967 ,0.001
C20:4n-6 0.625 0.022 0.497 n.s. 0.473 n.s.
C22:5n-6 0.746 0.003 0.909 ,0.001 0.820 0.001
C18:3n-3 0.930 ,0.001 0.723 0.005 0.566 n.s.
C20:5n-3 0.899 ,0.001 0.779 0.002 0.966 ,0.001
C22:5n-3 0.739 0.004 0.704 0.007 0.594 0.042
C22:6n-3 0.555 0.049 0.818 ,0.001 0.940 ,0.001
Correlation of individual GPL fatty acids after study:
PC PE PL
R P R P R P
C16:0 0.420 n.s. 0.281 n.s. 20.073 n.s.
C18:0 0.529 n.s. 20.363 n.s. 0.163 n.s.
C16:1n-7 0.943 ,0.001 0.952 ,0.001 0.313 n.s.
C18:1n-7 0.470 n.s. 0.547 n.s. 0.446 n.s.
C18:1n-9 0.878 ,0.001 0.739 0.004 0.807 ,0.001
C20:3n-9 0.341 n.s. 0.376 n.s. 20.034 n.s.
C18:2n-6 0.524 n.s. 0.833 ,0.001 0.498 n.s.
C18:3n-6 0.529 n.s. 0.489 n.s. 20.141 n.s.
C20:3n-6 0.816 ,0.001 0.913 ,0.001 0.874 ,0.001
C20:4n-6 0.681 0.010 0.657 0.015 0.427 n.s.
C22:5n-6 0.575 0.040 0.948 ,0.001 0.226 n.s.
C18:3n-3 0.875 ,0.001 0.761 0.003 0.853 ,0.001
C20:5n-3 0.255 n.s. 0.946 ,0.001 0.291 n.s.
C22:5n-3 0.577 0.039 0.885 ,0.001 0.016 n.s.
C22:6n-3 0.454 n.s. 0.725 0.005 0.729 0.005
n.s. not significant.
doi:10.1371/journal.pone.0033874.t004
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and decreased ARA contents in PL at the end of the study agree
with this hypothesis.
Our data show a trend towards increased EPA levels after the
supplementation of DHA in all studied fractions. This might be
related to the retroconversion of DHA to EPA. In humans a retro
conversation rate of at least 5% is observed [22]. This needs to be
considered when DHA is given as the only n-3 fatty acid source.
The omega-3 index, based on the relative EPA+DHA content,
is described as risk factor for coronary heart diseases [23]. We
found a high correlation between the omega-3 index in RBC PL
and GPL. It has to be determined, whether the omega-3 index
proposed by Harris and von Schacky is comparable to our results,
as different methods are applied and calculations of EPA+DHA
might be based on different definitions of total fatty acids [23].
However, our results show a strong correlation between PL and
GPL based omega-3 indices, therefore DHA and EPA proportions
of GPL analysed with our method may be applicable for an
omega-3 index determination.
In conclusion, the different responses of individual PL fractions
to an n-3 supplementation have to be considered for the
interpretation of changes in n-3 fatty acid status. Absolute and
relative changes in RBC PC seem to be higher then in PE or GPL.
The PL fatty acid composition is affected by different regulatory
mechanisms in the RBC membrane, which affect the contribution
of SM to total PL. Thus, we propose that our method for the
analysis of RBC GPL fatty acids is advantageous over the RBC PL
analysis, as changes of SM are excluded. Moreover, if the focus is
not on a specific GPL subfraction, our method is an excellent
alternative to monitor n-3 supplementation on fatty acid
composition as it avoids the labour intensive, time-consuming
and expensive separation of individual PL fractions.
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